St Jude: CE mark for Genesis migraine therapy the "starting point" of new neurostim opportunity
This article was originally published in Clinica
Executive Summary
St Jude Medical is confident that its Genesis peripheral nerve stimulation (PNS) therapy, which is now CE marked for treating chronic migraine, will play a significant role in driving the company's future growth. This is in spite of uncertainty among market spectators as to whether the use of neurostimulation devices for treating conditions outside its established indications, such as chronic back pain, will really take off.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.